News | Cardiovascular Surgery | February 16, 2017

First Edwards Intuity Elite Aortic Valve Implanted in Connecticut

Sutureless valve shortens procedure times, meaning less time the patient’s heart is stopped

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network

February 16, 2017 — Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were the first in Connecticut to implant the Edwards Intuity Elite sutureless aortic valve in two patients at Danbury Hospital. This new technology in aortic valve replacement (AVR) surgery presents a safe and effective option for patients with severe aortic valve disease. The valves were implanted using the Edwards Intuity valve system, a rapid deployment device approved by the U.S. Food and Drug Administration (FDA) in August 2016.

The American Heart Association estimates that more than 5 million Americans are diagnosed with heart valve disease each year. While the disease can occur in any combination of the four heart valves, the aortic and mitral valves are the most commonly affected.

Aortic stenosis mainly affects older people due to a build-up of calcium on the valve’s leaflets. Over a period of time, the aortic valve leaflets stiffen and do not completely open, blocking the normal flow of blood. Some of the symptoms associated with aortic stenosis include dizziness or fainting, shortness of breath, chest pressure or pain. Without treatment, the symptoms worsen over time and may lead to death within a few years. Treatment for valve disease depends on how much disease is in the valve.

The Edwards Intuity Elite valve is built upon the Perimount valve, which has been widely used for more than 20 years. The valve also uses technology from transcatheter heart valves to simplify placement and shorten the duration of the surgery. The Intuity valve differs from standard heart valves by only needing three guiding sutures for placement, instead of 12-15 sutures. 

Passik said, “Because the valves are not sutured in place, fewer steps are necessary, which translates to less time the heart is stopped and the patient is on the heart-lung machine.”  

“The cutting-edge treatment allows us to implant the aortic valve faster, thereby allowing more time to complete other procedures conducted simultaneously with the implantation,” said Gallagher, chief of cardiothoracic surgery. “We are very pleased to offer our patients another less invasive treatment option in AVR surgery.”

For more information: www.edwards.com

Related Content

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Overlay Init